CoChat

Potential Roles of Glucagon-Like Peptide 1 Receptor Agonists (GLP-1 RAs) in Nondiabetic Populations

Open access
Xu, Dan, Nair, Ankith, Sigston, Charlie, Ho, Chau, Li, Jia, Yang, Daya, Liao, Xinxue, Chen, Wei, Kuang, Ming, Li, Yanbing, Reid, Christopher, Xiao, Haipeng · 2022 · Cardiovascular Therapeutics
Cited by 50

The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.

Abstract

Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) have been observed in several large cardiovascular outcome trials to significantly reduce the incidence of major cardiovascular event (MACE) with type 2 diabetic patients. The clinical trials of GLP-1 RAs, including lixisenatide, exenatide, liraglutide, semaglutide, albiglutide, and dulaglutide, are associated with a significantly 14% lower risk of MACE in patients with T2DM and a history of CV disease, and with a nonsignificantly 6% lower risk in patients without history of CV disease. Some of the interpretation with GLP-1 RA trials suggested the possible role of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in primary prevention of cardiovascular diseases in nondiabetic individual, echoed by a recent editorial redefining the role of GLP-1 RAs being beyond glycaemic control. The narrative review provides an in-depth insight into GLP-1 RA use guideline in different countries and regions of the world and examines the safety and concern of GLP-1 RA use. The narrative review draws the comparison of GLP-1 RA use between diabetic and nondiabetic individual in terms of cardiovascular and metabolic benefits and points out the direction of future clinical trials of GLP-1 RAs in nondiabetic individuals. The focus of the review is on GLP-1 RAs’ preventive roles in nondiabetic individuals with cardiovascular disease, chronic kidney diseases, obesity, dyslipidaemia, hypertension, nonalcoholic fatty liver diseases, polycystic ovarian syndrome (PCOS), and perioperative complications of bariatric surgery, albeit in small studies and subset analysis of clinical trials of diabetic patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1155/2022/6820377

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 41 references

Research works printed but not linked: 38

  1. 10.1016/S0140-6736(87)91194-9 · DOI · Paper page
  2. 10.15277/bjdvd.2015.011 · DOI
  3. 10.1007/s13410-020-00879-4 · DOI
  4. Australian Medicine Handbook (AMH), 2022, Glucagon -like peptide analogues Australian Medicines Handbook
  5. Nice, 2015, Type 2 diabetes in adults: management
  6. 10.3760/cma.j.cn112138-20200704-00646 · DOI
  7. 10.1002/dmrr.3158 · DOI · Paper page
  8. 10.1056/NEJMoa1612917 · DOI · Paper page
  9. 10.1016/S0140-6736(19)31149-3 · DOI · Paper page
  10. 10.1056/NEJMoa1901118 · DOI · Paper page
  11. 10.1016/S0735-1097(18)31214-2 · DOI
  12. 10.1016/j.ahj.2015.07.014 · DOI
  13. 10.1007/s12020-015-0798-0 · DOI
  14. 10.1210/jc.2011-0585 · DOI · Paper page
  15. 10.1111/obr.12113 · DOI · Paper page
  16. 10.1136/bmj.g2646 · DOI · Paper page
  17. 10.1080/14656566.2019.1695779 · DOI · Paper page
  18. 10.2147/DDDT.S58459 · DOI · Paper page
  19. 10.1080/13543776.2020.1811851 · DOI · Paper page
  20. 10.1159/000521264 · DOI · Paper page
  21. 10.1016/S0140-6736(18)31773-2 · DOI · Paper page
  22. 10.1016/j.jpeds.2021.05.009 · DOI · Paper page
  23. 10.1016/j.atherosclerosis.2018.03.027 · DOI
  24. 10.1371/journal.pone.0135329 · DOI · Paper page
  25. 10.1111/1753-0407.12555 · DOI · Paper page
  26. 10.3389/fendo.2021.609110 · DOI · Paper page
  27. 10.1016/j.rbmo.2019.04.017 · DOI · Paper page
  28. 10.1016/j.metabol.2017.10.014 · DOI
  29. 10.1210/en.2017-00564 · DOI · Paper page
  30. 10.1016/S2213-8587(19)30157-3 · DOI · Paper page
  31. 10.1089/dia.2014.0188 · DOI · Paper page
  32. 10.1177/11795514211051697 · DOI · Paper page
  33. 10.1055/a-0818-6374 · DOI · Paper page
  34. 10.1111/j.1464-5491.2010.03020.x · DOI · Paper page
  35. 10.1111/dom.12414 · DOI · Paper page
  36. 10.1900/RDS.2014.11.202 · doi:10.1900/rds.2014.11.202
  37. 10.1111/dom.12386 · DOI · Paper page
  38. 10.1111/dom.12297 · DOI

Cited by

See all 50

Metadata

Authors
Xu, D., Nair, A., Sigston, C., Ho, C., Li, J., Yang, D., Liao, X., Chen, W., Kuang, M., Li, Y., Reid, C., & Xiao, H.
Venue
Cardiovascular Therapeutics
Publisher
Wiley
Published
2022-11-16
Volume
2022
Pages
1-9
ISSN
  • 1755-5914 (ISSN-L)
  • 1755-5922
OpenAlex
W4309323048
Cited by
50
References
41
FWCI
6.17
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Potential Roles of Glucagon-Like Peptide 1 Receptor Agonists (GLP-1 RAs) in Nondiabetic Populations. https://app.cochat.ai/papers/10.1155/2022/6820377
The paper
Xu, D., Nair, A., Sigston, C., Ho, C., Li, J., Yang, D., Liao, X., Chen, W., Kuang, M., Li, Y., Reid, C., & Xiao, H. (2022). Potential Roles of Glucagon-Like Peptide 1 Receptor Agonists (GLP-1 RAs) in Nondiabetic Populations. Cardiovascular Therapeutics. https://doi.org/10.1155/2022/6820377

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.